T1	Participants 207 261	adults with smear-positive pulmonary tuberculosis (TB)
T2	Participants 324 459	human immunodeficiency virus (HIV) infected participants who were not receiving antiretroviral therapy (ART) at TB treatment initiation
T3	Participants 695 793	Of 750 participants who received at least one dose of study treatment, 123 (16%) were HIV-infected
